Summit Global Investments Sells 378,461 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Summit Global Investments cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 51.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 350,739 shares of the company's stock after selling 378,461 shares during the quarter. Summit Global Investments' holdings in Takeda Pharmaceutical were worth $5,215,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at about $52,000. Cromwell Holdings LLC acquired a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at about $61,000. Venturi Wealth Management LLC lifted its stake in shares of Takeda Pharmaceutical by 554.7% in the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after purchasing an additional 4,260 shares during the period. Finally, Lindbrook Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 65.0% in the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 1.4%

Shares of NYSE:TAK traded up $0.21 during midday trading on Friday, reaching $15.01. The company's stock had a trading volume of 1,725,292 shares, compared to its average volume of 1,938,305. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.43. The firm has a market capitalization of $47.76 billion, a price-to-earnings ratio of 37.53, a PEG ratio of 0.24 and a beta of 0.26. The firm has a 50 day moving average price of $14.66 and a two-hundred day moving average price of $14.05. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The firm had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. As a group, analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.